Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F25%3A10504648" target="_blank" >RIV/00216208:11160/25:10504648 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/68407700:21340/25:00381206
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.pP9267U8n" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.pP9267U8n</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.nucmedbio.2025.108998" target="_blank" >10.1016/j.nucmedbio.2025.108998</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177
Popis výsledku v původním jazyce
The use of new radiopharmaceuticals labeled with lutetium-177 represents a successful translation of experimental results into clinical practice. Recent experimental data suggests that terbium-161 might well follow the example of lutetium-177 regarding applicability in nuclear medicine. Similarly to lutetium-177, the terbium-161 emits beta particles and gamma-radiation, although terbium-161 emits short-ranged conversion and Auger electrons, creating an effect that may eliminate smaller tumor metastases more effectively than lutetium-177. Terbium-161 may exert a higher radiobiological effect in the target tissues in comparison with lutetium-177, a difference which makes possible a reduction in the doses of radioactivity administered. Further, due to the similar chemical properties of lutetium-177 and terbium-161, similar radiolabeling techniques can be used. The differences found in preclinical experiments on radiotoxicity of the counterparts seem to be minor. Despite intensive progress, the number of preclinical studies on 161Tb-labeled agents is still not comparable to studies on lutetium-177. Clinical trials with 161Tb-labeled radiopharmaceuticals focused on the treatment of prostate cancer and selected neuroendocrine tumors have already begun, although none of them have been completed yet.
Název v anglickém jazyce
Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177
Popis výsledku anglicky
The use of new radiopharmaceuticals labeled with lutetium-177 represents a successful translation of experimental results into clinical practice. Recent experimental data suggests that terbium-161 might well follow the example of lutetium-177 regarding applicability in nuclear medicine. Similarly to lutetium-177, the terbium-161 emits beta particles and gamma-radiation, although terbium-161 emits short-ranged conversion and Auger electrons, creating an effect that may eliminate smaller tumor metastases more effectively than lutetium-177. Terbium-161 may exert a higher radiobiological effect in the target tissues in comparison with lutetium-177, a difference which makes possible a reduction in the doses of radioactivity administered. Further, due to the similar chemical properties of lutetium-177 and terbium-161, similar radiolabeling techniques can be used. The differences found in preclinical experiments on radiotoxicity of the counterparts seem to be minor. Despite intensive progress, the number of preclinical studies on 161Tb-labeled agents is still not comparable to studies on lutetium-177. Clinical trials with 161Tb-labeled radiopharmaceuticals focused on the treatment of prostate cancer and selected neuroendocrine tumors have already begun, although none of them have been completed yet.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
<a href="/cs/project/NU23-08-00214" target="_blank" >NU23-08-00214: Vývoj terbiem-161 značených biomolekul jako teranostických nástrojů v nukleární medicíně</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Nuclear Medicine and Biology
ISSN
0969-8051
e-ISSN
1872-9614
Svazek periodika
144-145
Číslo periodika v rámci svazku
May-June
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
9
Strana od-do
108998
Kód UT WoS článku
001429337000001
EID výsledku v databázi Scopus
2-s2.0-85217897336